誉衡生物Gloria |DJSeedin创新合作峰会临床公司路演汇报

誉衡生物是一家成立于2016年的创新生物制药公司，汇聚了具有国际视野的专业医药开发和管理团队。誉衡生物秉承开放、合作的核心价值观，立足国内放眼全球，聚焦肿瘤药物的研发、生产与销售。誉衡生物第一个商业化药品，基于全球领先的抗体研发技术平台开发的新型全人源抗PD-1单抗，赛帕利单抗注射液，首个获批适应症复发或难治性经典型霍奇金淋巴瘤有效率高达91.67%，将惠及淋巴瘤患者的长期生存。遵循ICH和GxP的规范，整合利用经广泛认证的先进技术平台和符合GMP要求的生物药生产线，与国内外合作伙伴通力合作开发最前沿的生物医药产品，提高用药可及性，降低用药负担是誉衡生物的使命。

Guangzhou Gloria Biosciences was formally founded in March 2016. It is a professional bio-pharmaceutical company based on the strategic cooperation between Gloria Pharmaceuticals and Shanghai WuXi AppTec. In August 2018, it won the favor and investments from famous investors such as Boyu Capital, 6 Dimensions Capital, Shiyu Capital, and successively partnered with wellknown companies such as WuXi AppTec, WuXi Biologics, WuXi Clinical and PPC Group. GloriaBio has more than 100 employees and consists of professional teams for R&D, production quality management and sales with an average work experience of more than 10 years. Among them, 41% have master's degree or above and 44% come from multinational pharmaceutical companies or has overseas study/work experience. With rich experience in innovative drug development and responsible for the smooth transition from preclinical to clinical stages, Gloria Biosciences’ research team is composed of high-caliber professionals.  Responsible for providing strong support for a variety of clinical trials, Gloria Biosciences’ clinical development team consists of professionals in clinical operations, data management, pharmacovigilance, project management, registration affairs.